(Q33256427)

24 July 2017

title

CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer (English)

1 reference

24 July 2017

Dhafir Al-azawi

1

1 reference

24 July 2017

Gabrielle Kelly

2

1 reference

24 July 2017

Eddie Myers

3

1 reference

24 July 2017

Enda W McDermott

4

1 reference

24 July 2017

Arnold D K Hill

5

1 reference

24 July 2017

Michael J Duffy

6

1 reference

24 July 2017

Niall O Higgins

7

1 reference

24 July 2017

language of work or name

English

0 references

publication date

5 September 2006

1 reference

24 July 2017

1 reference

24 July 2017

volume

6

1 reference

24 July 2017

page(s)

220

1 reference

Creative Commons Attribution 2.0 Generic

24 July 2017

copyright license

start time

5 September 2006

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2407-6-220

0 references

cites work

Serum tumor markers in breast cancer: are they of clinical value?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1590047

Neoadjuvant induction chemotherapy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1590047

Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1590047

Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1590047

High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1590047

Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1590047

Biochemical markers in breast cancer: which ones are clinically useful?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1590047

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1590047

Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1590047

Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1590047

Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment?

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-6-220

Serum markers and prognosis in locally advanced breast cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1590047

Prognostic value of CA 15.3 kinetics for metastatic breast cancer.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1590047

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

31 October 2018

1 reference

12 December 2020

Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study

1 reference

12 December 2020

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer

1 reference

12 December 2020

Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer

1 reference

12 December 2020

Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas

1 reference

12 December 2020

Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-6-220

1 reference

Dimensions Publication ID

24 July 2017

0 references

1 reference

24 July 2017

1 reference